Change Text Size

Click here for general information on participating in clinical studies.

We are currently recruiting for the following studies:

Mild memory loss (Mild Cognitive Impairment, MCI): A clinical research study of a medication for mild memory loss. Men and women 45 to 90 years of age who are in generally good health and have mild memory loss may be eligible to participate. Involvement in the study lasts 1 year and includes 9 visits. Webpage

Mild Alzheimer's Disease:Memory loss in Alzheimer's Disease (AD) is caused by the build-up of a protein called amyloid in the brain. We are testing a new medication called Flurizan, an amyloid-lowering agent, to see if it will slow the progression of AD. Men and women 55 years of age and older who are in generally good health and have mild AD may be eligible to participate. Involvement in the study lasts 13 months and includes 8 visits. Brochure
     (Brochure help*)

Mild to moderate Alzheimer's Disease: Memory loss in Alzheimer's Disease (AD) is caused by the build-up of a protein called amyloid in the brain. We are recruiting patients for two trials of new medication that stimulates the immune system to remove amyloid, to see if it will slow the progression of AD. Men and women 50 to 85 years of age who are in generally good health and have mild to moderate AD may be eligible to participate.
     IV Study: This trial lasts for 18 months with 12 months of follow-up monitoring. Study medication is given 6 times by intravenous (IV) injection.
     IM Study: This trial lasts for 36 months and includes one dose of study medication given by intramuscular (IM) injection.

Mild to moderate Alzheimer's Disease (Aladdin Study): The Aladdin study is designed to see if a drug called leuprolide, which is currently approved to treat other medical conditions, will slow the progression of Alzheimer's Disease (AD). Men and women 65 years of age and older who have mild to moderate AD and have been taking an approved medication for AD for at least 4 months may be eligible to participate. Involvement in the study lasts for 56 weeks and includes 12 visits. You will receive the study medication 8 times in the form of a small implant. Brochure
     (Brochure help*)

CADASIL: We are testing a medication already approved for Alzheimer’s Disease to see if will help improve cognitive symptoms in patients with CADASIL. The medication enhances a brain chemical called acetylcholine which is necessary for learning and memory. Men and women 25 to 70 years of age who have been diagnosed with CADASIL and have cognitive impairment may be eligible to participate. Involvement in the study lasts for 18 weeks and includes 5 visits. Webpage    Brochure
     (Brochure help*)

Caregiver Study: We are conducting a study of a new treatment for caregivers of people with dementia. We believe that helping the caregiver will help the entire family as well as the patient. Study participants will receive doctor visits, comprehensive assessments, and study medication free of charge. The study is designed to help caregivers who may be feeling stressed, nervous or depressed; but participants do not have to be clinically depressed in order to be included. Webpage     Brochure
     (Brochure help*)

Imaging Studies: Patients with mild cognitive impairment (MCI), vascular cognitive impairment (VCI) or vascular dementia, as well as caregivers or family members without memory impairment may be eligible to participate in our diffusion-tensor imaging (DTI) study. Participants have a DTI scan of the brain, which is very similar to an MRI scan, and take some tests of memory and thinking. Webpage

*

Adobe Acrobat Reader is needed to view brochures. Click the link to download the program free.